<DOC>
	<DOCNO>NCT00041704</DOCNO>
	<brief_summary>Anidulafungin antifungal agent echinocandin class highly active vitro fluconazole resistant Candida specie . The efficacy anidulafungin demonstrate various animal model fluconazole-resistant mucosal disease ; well , Phase 2 Esophageal Candidiasis study . This study intend offer patient FRMC alternate therapy amphotericin B agent whose efficacy and/or safety inadequate treatment disease .</brief_summary>
	<brief_title>The Safety Efficacy Intravenous Anidulafungin Treatment Azole-Refractory Mucosal Candidiasis ( FRMC )</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Diagnosis definite azolerefractory mucosal candidiasis ( oral oropharyngeal candidiasis esophageal candidiasis ) , i.e. , patient respond prior 14day course fluconazole dose least 200 mg daily azole ( e.g . voriconazole ) Grade 1 high mucosal disease microscopic culture confirmation yeast Pregnant female Hypersensitivity anidulafungin echinocandin therapy Hypersensitivity Tween 80 ( polysorbate 80 ) tartaric acid Abnormal blood chemistry : Bilirubin &gt; 2 time upper limit normal ; AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) &gt; 4 time upper limit normal Less four week since prior participation investigational drug device study exception antiretroviral agent license agent Patients take systemic antifungal therapy study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Azole-Refractory Mucosal Candidiasis</keyword>
	<keyword>Mucosal Candidiasis</keyword>
</DOC>